Bank of India Mid Cap Fund
The scheme is to generate long-term capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Growthvine rating: 1/5 — ranked #28 of 33 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹10.61 (as of 2026-08-21) |
|---|
| AUM | ₹725 Cr |
|---|
| Expense ratio | 2.03% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -12.91% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 64.0% of NIFTY Midcap 150's upside and 85.2% of its downside.
Market cap allocation
| Large cap | 7.8% |
|---|
| Mid cap | 72.2% |
|---|
| Small cap | 20.0% |
|---|
Concentration
| Top 5 holdings | 21.6% |
|---|
| Top 10 holdings | 35.6% |
|---|
| Total holdings | 53 |
|---|
| Index overlap | 27.1% |
|---|
| Active share | 72.9% |
|---|
Top holdings
- Aurobindo Pharma Ltd. — 5.4%
- Abbott India Ltd. — 4.9%
- Bharti Hexacom Limited — 4.4%
- Multi Commodity Exchange of India Ltd — 3.9%
- NIPPON LIFE INDIA ASSET MANAGEMENT LIMITED — 3.0%
- J.K. CEMENT LTD — 2.9%
- Mankind Pharma Limited — 2.9%
- Lloyds Metals and Energy Limited — 2.8%
- UNO Minda Limited — 2.8%
- Max Financial Services Limited — 2.6%
Top sectors
- Pharma & Biotech — 15.8%
- Banking & Financial — 15.4%
- Electricals — 7.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 8.3% | Q2 | #14 of 31 |